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Coxsackie and adenovirus receptor (CAR) was ﬁrst known as a virus receptor. Recently, it is also known to have tumor suppressive
activity such as inhibition of cell proliferation, migration, and invasion. It is important to understand how CAR expression can
be regulated in cancers. Based on an existence of putative Sp1 binding site within CAR promoter, we investigated whether indeed
Sp1 is involved in the regulation of CAR expression. We observed that deletion or mutation of Sp1 binding motif (−503/−498)
prominently impaired the Sp1 binding aﬃnity and activity of CAR promoter. Histone deacetylase inhibitor (TSA) treatment
enhanced recruitment of Sp1 to the CAR promoter in ChIP assay. Meanwhile, Sp1 binding inhibitor suppressed the recruitment.
Exogenous expression of wild-type Sp1 increased CAR expression in CAR-negative cells; meanwhile, dominant negative Sp1
decreased the CAR expression in CAR-positive cells. These results indicate that Sp1 is involved in regulation of CAR expression.
1.Introduction
Coxsackie and adenovirus receptor (CAR) has been known
only as a viral receptor [1], and a lot of eﬀorts to increase
i t se x p r e s s i o n a ll e v e lh a v eb e e ne n d e a v o r e dt oi m p r o v eg e n e
delivery eﬃciency for virus-mediated cancer gene therapy.
Moreover, recently, CAR is also known to have tumor
suppression activity. To support this, deﬁciency of CAR
expression has been observed in many cancer cell lines and
gastriccancertissue,andrestorationofCARexpressionleads
to growth inhibition of those cancer cell lines [2–5]. To
further substantiate the functional role of CAR, deﬁciency of
CAR is closely associated with downregulation of α-catenin,
which is involved in inhibition of cancer cell growth and
motility [6]. Additionally, in gastric cancer patients loss of
CAR expression signiﬁcantly correlates with poor prognosis
of gastric cancer, suggesting its functional contribution to
cancer pathogenesis [6, 7]. Despite of such importance in
cancer biology as well as in cancer gene therapy, little is
known about how CAR is regulated at expression level.
A few regulation mechanisms including epigenetic con-
trol and oncogenic signaling pathway have been suggested
to be involved in CAR expression. Histone deacetylase
(HDAC) inhibitors, FR901228 [8] and trichostatin A (TSA)
[9], induce CAR mRNA expression through epigenetic
chromatin remodeling such as histone acetylation. Raf-
MEK-ERK signaling pathway is also known to be involved
in CAR expression regulation [10]. In urogenital cancer cells,
Pong et al. group [8] characterized a distinct region (−585
and −400bp)ofCARpromoter,so-calledcorepromoterthat
exerts strong promoter activity, containing several binding
motifs including Sp1 transcription factor. Based on this
report, we investigated whether indeed Sp1 is involved in
the regulation of CAR expression in wide range of cell2 Journal of Biomedicine and Biotechnology
types. Here, using various cancer cell lines we demonstrated
that Sp1 plays an important role in the regulation of CAR
expression.
2.MaterialsandMethods
2.1. Cell Culture and Reagents. Cell culture reagents were
purchased from GIBCO BRL (Rockville, MD, USA).
HCT116 (CAR-positive colon cancer), PC-3 (CAR-negative
prostate cancer), and SW480 (CAR-positive colon cancer)
were cultured in RPMI 1640 supplemented with 10% FBS,
penicillin (100 units/mL), and streptomycin (100μg/mL) at
37◦Ci n5 %C O 2. HepG2 (CAR-positive liver cancer) and
HeLa cells (CAR-positive cervical cancer) were cultured in
DMEM, and MCF-7 cells (CAR-negative breast cancer cell
line) were cultured in MEM. Mithramycin (MTM) and TSA
were purchased from Sigma (St. Louis, MO).
2.2. Plasmid and Transfection. As e to fC A Rp r o m o t e r
reporter constructs was kindly provided by Pong et al.
[8]. 1213/−552 and −585/−400 constructs were generated
by cloning it into pGL3-Basic (at Xho Ia n dHindIII
restriction sites) using a PCR-based technique. Mutant
of the −585/−400 core reporter construct was made by
replacing the Sp1 binding sequence (5 -CGGGGCGGAG-
3  → CGTTTTTGAG). Sp1 expression vector (pCMV-WT-
Sp1) was kindly supplied by Dr. Robert Tjian (University of
California, Berkeley, CA) and dominant negative Sp1 (DN-
Sp1) was from Dr. Gerald Thiel (University of the Saarland
Medical School Hamburg, Germany). To match the same
vector backbone, DN-Sp1 was subcloned into pCMV vector.
Transfection and promoter activity assay were performed
according to our previous report [11].
2.3. Semiquantitative RT-PCR. Extraction of total cellu-
lar RNA and synthesis of ﬁrst strand were performed
as previously reported [11]. The primer sequences of
CAR used for Semiquantitative PCR were as follows:
forward, 5 -TGCTGTCGTAAAAAGCGCAG-3 ;r e v e r s e ,5  -
CTATACTATAGACCCATCCT-3 . The PCR conditions were
as follows: hot starts at 95◦Cf o r3m i nf o l l o w e db y2 5c y c l e s
of ampliﬁcation at 94◦C for 15sec, 55◦C for 20sec, and 72◦C
for 30sec, and an extension step at 72◦C for 7min. GAPDH
was used as a control: forward, 5 -TCGTGGAAGGACTCA-
TGACC-3 ;r e v e r s e ,5  -TCCACCACCCTGTTGCTGTA-3 .
PCR products were analyzed on 1% agarose gels.
2.4. Western Blotting. Western blotting was performed as
previously reported [11] using primary antiacetylated H3
antibody (Ac-H3; Upstate Biotechnology, Lake Placid, NY)
(1:3000) and HRP-conjugated secondary antibody.
2.5. Electrophoretic Mobility Shift Assay (EMSA). EMSA
was performed according to our report [11], and for the
preparation of the probe, 26bp oligonucleotides compris-
ing Sp1 binding site (−513 to −488: 5 -GGTGCAGGC-
GGGGCGGAGGGTAGGAG-3 ) were annealed and labeled
with [γ-32P] ATP. For the mutant probe, the underlined Sp1
bindingsequencewasreplacedbyTTTTTG.Forcompetition
experiments, unlabeled probes were added to the reaction
mixture at 200-fold excess molar concentration. In the
supershift assays, 1.5μg of Sp1 antibody (Santa cruz) was
preincubated for 20min at room temperature. MTMs were
preincubated for 1h at 4◦C with the labeled probe prior to
mixing with nuclear proteins [12].
2.6. Chromatin Immunoprecipitation (ChIP) Assay. ChIP
assay was performed as described previously [11]w i t h
minor modiﬁcation. Chromatin was precipitated with anti-
Sp1 (Santa Cruze Biotechnology, Santa Cruz, CA) or anti-
acetyl histone H3 (Upstate Biotechnology, Lake Placid, NY).
Puriﬁed DNA fragments were subjected to PCR reaction
[98◦C (3min), 29 cycles of 98◦C (30s), 62◦C( 3 0 s ) ,a n d
72◦C (1min), then 72◦C (7min)] with a primer set,
Forward: 5 -ACAGGTCGCATCCCGTGAG-3 ,R e v e r s e :5  -
CAGCCCGTCTCCCACATACTG-3  [8].
2.7. Ad-β-Gal Transduction. For the analysis of adenovi-
ral transduction eﬃciency, MCF-7 cells were treated by
TSA (25ng/mL) for 24h with or without pretreatment of
mithramycin for 30min (50 and 100nM) and transferred
to Sonic Seal Slide 4-well plates (Nalge Nunc, North Aurora
Road, Naperville, IL). Cells were infected at an MOI of 50
with Ad-β-gal (Neurogenex, Gwanak-Gu, Seoul, Republic of
Korea) for 1h in the serum free medium. The infected cells
were maintained in complete medium for an additional 24h
and washed twice with PBS and ﬁxed for 15 minutes with
PBS containing 3.7% formaldehyde. After washing twice
withPBSfor5minutes,theﬁxedcellswerestainedwithX-gal
staining solution (2mM MgCl2, 5mM potassium ferri/ferro
cyanide, 1mg/mL X-gal, 0.02% NP-40) in the dark room at
37◦C for 6 hours. Photographs of the whole or magniﬁed
cells were taken. β-Galactosidase-positive cells were counted
from three nonoverlapping ﬁelds.
2.8. Statistical Analysis. A l lv a l u e sa r ee x p r e s s e da sm e a n±
S.D. Statistical comparison between experimental groups
was carried out using Student’s t-test. P values <0.05 were
considered to be statistically signiﬁcant.
3. Results and Discussion
3.1. A Putative Sp1 Binding Site within the Core Promoter
Is Required for CAR Promoter Activity. We ﬁrst examined
the promoter activity of CAR gene with a series of reporter
gene constructs (Figure 1(a)) containing serially deleted
CAR promoter region, similar to previous report [8], and
we further tested it in several diﬀerent cancer cell types
beyond urogenital cancer cell lines. Consistent with previous
report [8], deletion of a common region that comprises the
core promoter containing Sp1 binding motif (−503/−498)
severely impaired the CAR promoter activity in HCT116
and HeLa cell lines (Figures 1(b) and 1(c)). Additionally,
mutation of Sp1 binding motif within the core promoter was
enough to impair the promoter activity in CAR-positive cell
lines, such as HCT116, HeLa, SW480, and HepG2 cell line
(Figure 1(d)).Journal of Biomedicine and Biotechnology 3
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Figure 1:ComparativeanalysisofCARpromoteractivity.(a)SchematicdescriptionofCARgenepromotercontainingspeciﬁctranscription
factor binding sites and its deletion constructs. The luciferase reporter gene constructs were cloned into pGL3 vector. (b, c) Each CAR
promoter-luciferasereporterconstructwascotransfectedintotwodiﬀerentCAR-positivecellswithβ-galactosidasegene. ∗P = 0.0003, ∗∗P<
0.001 relative to other constructs, not pGL3. Bars represent SD. (d) Either Wt or mut of the core promoter (−585/−400) was cotransfected
into four diﬀerent CAR-positive cells with β-galactosidase gene. From total cell extracts, luciferase activities were examined and normalized
by β-galactosidase activity. The relative luciferase activities were determined by statistical analysis of three independent experiments. #P<
0.05 relative to each of wild-type. Bars represent the mean ± SD.4 Journal of Biomedicine and Biotechnology
0
2
4
6
8
10
12
14
Vector Sp1 DN-Sp1
-MCF7-
∗∗ ∗
R
e
l
a
t
i
v
e
l
u
c
i
f
e
r
a
s
e
a
c
t
i
v
i
t
y
/
∗∗∗
Reporter: −585/−400 Wt promoter
β
-
g
a
l
(
×
1
0
4
)
(a)
0
2
4
6
8
10
12
14
16
-PC3-
Vector Sp1 DN-Sp1
∗∗ ∗
R
e
l
a
t
i
v
e
l
u
c
i
f
e
r
a
s
e
a
c
t
i
v
i
t
y
/
∗∗∗
Reporter: −585/−400 Wt promoter
β
-
g
a
l
(
×
1
0
4
)
(b)
0
2
4
6
8
10
12
14 -MCF7-
R
e
l
a
t
i
v
e
l
u
c
i
f
e
r
a
s
e
a
c
t
i
v
i
t
y
/
pGL3 Wt Mut : −585/
−400
###
## #
DMSO
MTM
Ectopic expression: Sp1
β
-
g
a
l
(
×
1
0
4
)
(c)
0
2
4
6
8
10
12
14
R
e
l
a
t
i
v
e
l
u
c
i
f
e
r
a
s
e
a
c
t
i
v
i
t
y
/
pGL3 Wt Mut : −585/
−400
###
## #
-PC3-
DMSO
MTM
Ectopic expression: Sp1
β
-
g
a
l
(
×
1
0
4
)
(d)
Figure 2: Eﬀect of the mutation in Sp1 binding motif or Sp1 on CAR promoter activity. (a, b) For the examination of the eﬀect of Sp1
on the promoter activity, either Sp1 or its dominant negative form (Sp1 DN) was cotransfected into MCF-7 (a) and PC-3 cells (b) with
reporter construct of core promoter and β-galactosidase gene in the presence or absence of mithramycin. ∗P<0.05, ∗∗∗P>0.05 relative to
pCMV vector control, ∗∗P<0.05 relative to Sp1 control. (c, d) For the examination of the eﬀect of Sp1 binding site on the core promoter
activity in response to ectopic expression of Sp1, either wild type or mutant type of core promoter was cotransfected with Sp1 and β-
galactosidase into MCF-7 (c) and PC-3 (d), and the following procedures were identical to above case. From total cell extracts, luciferase
activities were examined and normalized by β-galactosidase activity. The relative luciferase activities were determined by statistical analysis
of three independent experiments. #P = 0.0003, ###P<0.05 relative to pGL3 vector control, ##P<0.05 relative to wild-type core promoter
(−585/−400) DMSO. Bars represent the mean ± SD.
3.2. Exogenous Expression of Sp1 Transactivates the Core
Promoter Activity. Next, to examine how important the Sp1
transcription factors are involved in the transactivation, we
compared the eﬀects of ectopic expressions of Sp1 and
dominant negative Sp1 (Sp1 DN) on the core promoter
activity.TheexogenousexpressionofSp1increasedtheactiv-
ities more than 2-fold, compared with vector-transfected
control cells in MCF-7 and PC-3 cell lines (Figures 2(a) and
2(b)). On the contrary, the ectopic expression of Sp1 DN
couldnot regulate the activity. However, mithramycin treat-
ment, which is known as blocking transcriptional activity
of Sp1 family transcription factors through binding to G/C-
rich region [12, 13], signiﬁcantly suppressed the promoter
activity in the cells expressed by ectopic Sp1, but not by Sp1
DN (Figures 2(a) and 2(b)). Likeness, the ectopic expression
of Sp1 enhanced the core promoter activities more than 10-
fold, compared with pGL3 control vector in the same cell
lines (Figures 2(c) and 2(d)). However, under the mutation
of Sp1 binding site in the core promoter, it exerted very low
activity despite of ectopically Sp1 expression. Mithramycin
treatment also signiﬁcantly suppressed the core promoter
activity (Figures 2(c) and 2(d)), suggesting that Sp1 binding
inhibition to CAR promoter has eﬀect on transactivation
activity of CAR gene.
3.3. Sp1 Directly Binds to CAR Promoter. To directly demon-
strate the involvement of Sp1, we performed EMSA and
observed complex formation between DNA probe and Sp1Journal of Biomedicine and Biotechnology 5
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Figure 3: Sp1 binds to its putative binding motif within the core promoter. (a) Labeled probe and cold wild or mutant type probes used
for competition assay were used as described in Section 2. The closed triangle indicates the Sp1-DNA probe complex. (b) Labeled probe
was preincubated with either MTM or DMSO (vehicle) for 1h at 4◦C before incubation with the nuclear proteins. (c, d) Chromatin
immunoprecipitation assay. Each of cell lysates was extracted from MCF-7 cells or HepG2 (e) cells after treatment either by TSA or MTM.
Chromatin immunoprecipitation was performed with anti-Sp1, anti-acetyl histone H3, and then PCR was carried out with primers ﬂanking
Sp1 binding site.
protein (lane 2 in Figure 3), which was abolished by wild-
type cold competitor, but not by mutated one (lanes 3 and
4i nFigure 3). Additionally, the complex was supershifted by
Sp1 antibody (lane 5 in Figure 3). Meanwhile, mutant probe
did not show any complex formation (lane 6 in Figure 3).
Treatment with mithramycin (MTM), which is known to
inhibit Sp1 binding by targeting GC-rich region of DNA
[12, 14], prevented the complex formation between Sp1 and
DNA probe in a dose-dependent manner (Figure 3(b)). To
demonstrate Sp1 directly binding to CAR gene promoter,
we also performed ChIP assay using Sp1 antibody. TSA
treatment capable of inducing CAR expression increased
Sp1 binding to CAR promoter, as reﬂected on enhanced
PCR product in MCF-7 cells (Figure 3(c)). Furthermore,
under open chromatin structure by TSA, we scrutinized
relationship between acetyl-histone H3 and Sp1 binding
inhibition with CAR promoter into MCF-7 cells or CAR-
negative cell line. As shown in Figure 3(d), even if enhancing6 Journal of Biomedicine and Biotechnology
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Figure 4: Eﬀects of MTM on CAR promoter activity and mRNA expressions. HCT116 (a), HeLa (c), and HepG2 (e) were treated with
either MTM or DMSO (vehicle) for 24h at the concentration indicated. The mRNA expressions of CAR and GAPDH used as an internal
control were examined by Semiquantitative RT-PCR. Core promoter reporter construct was cotransfected with β-galactosidase into the
three diﬀerent cells and followed by treatment with either MTM or DMSO for 24h at the concentration indicated (b, d, and f). The relative
luciferase activity was determined by statistical analysis of three independent experiments. Bars represent the mean ± SD.Journal of Biomedicine and Biotechnology 7
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Figure 5: Eﬀects of Sp1 or MTM on TSA-induced CAR promoter activity and mRNA expression. HepG2 (a, b) and MCF-7 (c) cells were
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expression of CAR mRNA was determined. The mRNA levels of lane1 were set to 1.0.8 Journal of Biomedicine and Biotechnology
MTM (nM) 50
−
− −
+ ++
100
TSA (25ng/mL)
(a)
0
20
40
60
80
100
β
-
g
a
l
p
o
s
i
t
i
v
e
c
e
l
l
s
(
%
)
M T M(n M) 50 100
−
−−
+ + + TSA (25ng/mL)
(b)
Figure 6: Eﬀect of Sp1 binding on infectivity of adenoviral con-
taining β-gal. (a) MCF-7 cells were treated by TSA with or without
pretreatment of mithramycin and infected by Ad-β-gal (50MOI).
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Sp1 binding to CAR promoter, along with acetyl-histone H3
(lane 4), in the presence of TSA, the association between
Sp1 and acetyl-histone H3 was disrupted by Sp1 binding
inhibition, mithramycin A, indicating that Sp1 can regulate
CAR gene under open-chromatin structure by TSA, and Sp1
cannot bind CAR promoter in the presence of both TSA
and Sp1 binding inhibitor into CAR-negative cell, MCF-7
cells. Besides, in CAR-positive cell, HepG2 cell line, in which
CAR expression is basically high, Sp1 binding inhibitor itself
led to dissociate binding between Sp1 and CAR promoter
(Figure 3(e)). Taken together, Sp1 directly regulates CAR
gene through binding at CAR promoter.
3.4. Mithramycin Prevents TSA-Induced CAR mRNA Expres-
sion. Based on the observation that MTM could eﬀectively
prevent Sp1 binding to CAR promoter, as shown in the
previous EMSA and ChIP assay, we examined cellular eﬀect
ofMTMonCARmRNAexpression.Asexpected,MTMdose
dependently suppressed CAR mRNA expression in a similar
pattern to its eﬀect on promoter activity in all cell lines tested
(Figure 4). To further substantiate the involvement of Sp1
in transcriptional regulation of CAR gene, we identiﬁed the
eﬀect of MTM under combinational TSA treatment, which
is known to induce CAR expression through epigenetic
regulation, such as histone acetylation, in CAR-negative cells
[9]. MTM suppressed both the enhanced CAR promoter
activity and CAR mRNA expression, which were induced by
TSA treatment, in a dose-dependent manner (Figures 5(a),
5(c),a n d5(d)). Furthermore, as shown in Figure 5(c), CHIP
assay (Figure 3(d)) reﬂected on CAR mRNA expression
through the association between Sp1 and acetyl-histone
H3, indicating that Sp1 can express CAR mRNA under
open-chromatin structure by TSA, and Sp1 cannot regulate
CAR mRNA in the presence of both TSA and Sp1 binding
inhibitor into CAR-negative cell, MCF-7 cells. However, the
induction eﬀect by TSA was not prominent in HepG2 cell,
which might be due to high expressional level at basal state.
Furthermore, the inhibition eﬀect of MTM was constant
to a certain ﬁxed level determined by the concentration of
MTM treated, regardless of how much histone acetylation
was induced by TSA as shown in hyperacetylated histone
3( Figure 5(b)), suggesting that Sp1 plays critical role in
the CAR regulation, in addition to chromatin remodeling,
although which allows free access of many transcription
factors.
3.5. Sp1 Regulates the Expression of CAR mRNA to Carry out
Function as Adenovirus Receptor in Cancer Cell. We checked
the eﬀect of Sp1 overexpression on CAR expression. Ectopic
expression of wild-type Sp1 (WT-Sp1) induced CAR mRNA
expression in CAR-negative MCF-7 cells in the presence of
TSA (Figure 5(e)) but not absence of TSA (data not shown).
Meanwhile, ectopic expression of dominant negative Sp1
(DN-Sp1) suppressed the mRNA expression in CAR-positive
HCT116 cells (Figure 5(f)), in a dose-dependent manner.
Eventually, the expression level of CAR regulated by Sp1 may
have eﬀect on its function as receptor for adenoviral entry in
the cancer cells. Therefore, based on data shown previously,
we could practically substantiate the importance of Sp1
binding through in vivo study, by demonstrating that MTM
treatment prevented the enhanced uptake of adenovirus
vector containing β-gal transgene in MCF-7 cells, which
was mediated by TSA-induced CAR expression (Figure 6).
Consistent with the previous report [15–17], TSA treatment
by itself made adenoviral infection increase up to 70% into
MCF-7 cell line (Figure 6). However, by mithramycin treat-
ment, the inhibition of Sp1 binding at CAR gene promoter
eventually reduced the eﬀect of adenoviral infection into
MCF-7 cell line below 20%, indicating that the decline of
CARexpressionbySp1bindinginhibitionwasnotenoughto
infect adenoviral containing transgene. Therefore, we could
further conﬁrm that Sp1 was essential for enhancing the
mRNA level of CAR gene to carry out function as adenovirus
receptor in cancer cell.
CAR has recently attracted much attention as being
regarded as tumor suppressor in addition to as a primary
receptor of adenoviral vector used for cancer gene therapy.
Nonetheless, little is known about the regulation mecha-
nism of CAR expression. Through this study, we could be
able to further substantiate HDAC inhibitor-induced CAR
expression, which comprises Sp1 activation for its binding
to open chromatin structure, and also we could directly
demonstrate the involvement of Sp1 transcription factor byJournal of Biomedicine and Biotechnology 9
EMSA, mithramycin treatment, and ChIP assay. Eventually,
we could further clarify the underlying mechanism of HDAC
inhibitors by demonstrating that the Sp1 plays a critical role
in the regulation of CAR expression.
4. Conclusions
Transcription factor Sp1 plays common role in regulating
CAR expression in diverse cancer cells, such as HCT116
(CAR-positive colon cancer), PC-3 (CAR-negative prostate
cancer), SW480 (CAR-positive colon cancer), HepG2 (CAR-
positive liver cancer), HeLa cells (CAR-positive cervical can-
cer), and MCF-7 cells (CAR-negative breast cancer cell line).
In case of CAR-positive cancer cell lines, CAR expression was
downregulated through Sp1 binding inhibitor. Meanwhile,
under open chromatin structure by HDAC inhibitor TSA,
Sp1 also regulated CAR expression in CAR-negative cancer
cell lines. In view of regulating CAR expression, it would be
possible to be crosstalk between HDAC inhibitor and Sp1.
Therefore, it would be of interest to study whether HDAC
inhibitor could make Sp1 induce CAR expression through
Sp1 acetylation.
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